Current options in antifungal pharmacotherapy

Pharmacotherapy

Volumn 28, Issue 5 PART 1, 2008, Pages 614-645

  Mohr, John ^a,e   Johnson, Melissa ^b   Cooper, Travis ^c   Lewis II, James S ^d   Ostrosky Zeichner, Luis ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c METHODIST DALLAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Amphotericin B; Antifungal drugs; Invasive aspergillosis; Invasive fungal infection; L AmB; Liposomal amphotericin B; Polyenes

Indexed keywords

1 [3 [4 (4 CYANOPHENYL) 2 THIAZOLYL] 2 (2,5 DIFLUOROPHENYL) 2 HYDROXYBUTYL] 4 [1 [N METHYL N [3 [2 (METHYLAMINO)ACETOXYMETHYL] 2 PYRIDINYL]CARBAMOYLOXY]ETHYL] 1H 1,2,4 TRIAZOL 4 IUM CHLORIDE; 4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; CASPOFUNGIN; CYCLODEXTRIN; CYCLOSPORIN; DIGITALIS; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; TACROLIMUS; TERBINAFINE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BACKACHE; BLASTOMYCOSIS; BLURRED VISION; BRONCHOSPASM; CANDIDEMIA; CANDIDIASIS; CHILL; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COLOR DISCRIMINATION; COMBINATION CHEMOTHERAPY; CONGENITAL MALFORMATION; CONVULSION; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FEVER; FUNGEMIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HISTOPLASMOSIS; HOT FLUSH; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; INJECTION SITE REACTION; LIVER FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; MOULD; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHLEBITIS; PHOTOPHOBIA; PHOTOSENSITIVITY; QT PROLONGATION; RASH; RESPIRATORY DISTRESS; REVIEW; RIGOR; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THORAX PAIN; THROMBOPHLEBITIS; TORSADE DES POINTES; TREATMENT RESPONSE; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING; YEAST;

ANTIFUNGAL AGENTS; AZOLES; ECHINOCANDINS; HUMANS; MYCOSES; POLYENES;

EID: 42949144287     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.5.614     Document Type: Review

References (268)

1. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006;25:419-25.
2. Rex JH, Walsh TJ, Anaissie EJ. Fungal infections in iatrogenically compromised hosts. Adv Intern Med 1998;43:321-71.
3. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9.
4. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5.
5. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31.
6. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
7. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003;16:533-7.
8. Ostrosky-Zeichner L. Prophylaxis for invasive candidiasis in the intensive care unit: is it time? Crit Care Med 2005;33:2121-2.
9. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005;43:235-43.
10. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the united States during 1989-1999. Clin Infect Dis 2002;35:627-30.
11. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol 2002;40:852-6.
12. Lopez J, Pernot C, Aho S, et al. Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies. J Hosp Infect 2001;48:122-8.
13. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005;49:4555-60.
14. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-54.
15. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803; quiz 804-5.
16. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Inlect Dis 2001;32:358-66.
17. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-40.
18. Mihu CN, King E, Yossepovitch O, et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation [published online ahead of print July 27, 2007]. Transpl Infect Dis. Available from http://www.blackwell-synergy.com/doi/abs/10. 1111/j.1399-3062.2007.00272.x.
19. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
20. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes: 13 aspergillus study group. Medicine (Baltimore) 2000;79:250-60.
21. Rex JH. Galactomannan and the diagnosis of invasive aspergillosis. Clin Infect Dis 2006;42:1428-30.
22. Saag MS, Graybill RJ, Larsen RA, et al, for the Infectious Diseases Society of America. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000;30:710-18.
23. Centers for Disease Control and Prevention, Division of Bacterial and Mycotic Diseases. Cryptococcosis. October 2005. Available from http://www.cdc.gov/ncidod/dbmd/diseaseinfo/cryptococcosis_t.htm. Accessed May 15, 2007.
24. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-51.
25. White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992;165:960-3.
26. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons, 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002;137:435-78.
27. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006;25:215-29.
28. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53.
29. Wheat LJ, Goldman M, Sarosi G. State-of-the-art review of pulmonary fungal infections. Semin Respir Infect 2002;17:158-81.
30. Crum NF, Potter M, Pappagianis D. Seroincidence of coccidioidomycosis during military desert training exercises. J Clin Microbiol 2004;42:4552-5.
31. Centers for Disease Control and Prevention, Division of Bacterial and Mycotic Diseases. Blastomycosis. October 2005. Available from www.cdc.gov/ncidod/dbmd/diseaseinfo/blastomycosis_t.htm. Accessed May 15, 2007.
32. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004;48:693-715.
33. Dodds Ashley ES, Lewis R, Lewis J, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43:S28-39.
34. Ramos H, Valdivieso E, Gamargo M, Dagger F, Cohen BE. Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J Membr Biol 1996;152:65-75.
35. Matsuoka S, Ikeuchi H, Umegawa Y, Matsumori N, Murata M. Membrane interaction of amphotericin B as single-length assembly examined by solid state NMR for uniformly 13C-enriched agent. Bioorg Med Chem 2006;14:6608-14.
36. Bahmed K, Bonaly R, Benallaoua S, Coulon J. Effect of sub-inhibitory concentrations of amphotericin B on the yeast surface and phagocytic killing activity. Process Biochem 2005;40:759-65.
37. Saxena S, Bhatnagar PK, Ghosh PC, Sarma PU. Effect of amphotericin B lipid formulation on immune response in aspergillosis. Int J Pharm 1999;188:19-30.
38. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11:1463-71.
39. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard." Clin Infect Dis 2003;37:415-25.
40. Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995;155:2429-35.
41. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia study group and the national institute. N Engl J Med 1994;331:1325-30.
42. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72.
43. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian candidemia study group. Eur J Clin Microbiol Infect Dis 1997;16:337-45.
44. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
45. Anaissie E, White M, Azun O. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstract]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1995:abstract LM-21.
46. Ito JI, Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 2005;40(suppl 6):S384-91.
47. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-12.
48. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
49. de Lalla F, Pellizzer G, Vaglia A, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995;20:263-6.
50. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccocal meningitis. N Engl J Med 1979;301:126-31.
51. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317:334-41.
52. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases mycoses study group and AIDS clinical trials group. N Engl J Med 1997;337:15-21.
53. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.
54. Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987;5:1985-93.
55. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-201.
56. Gurwith MJ, Stinson EB, Remington JS. Aspergillus infection complicating cardiac transplantation. Report of five cases. Arch Intern Med 1971;128:541-5.
57. Stevens DA, Kan VL, Judson MA, et al, for the Infectious Diseases Society of America. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30:696-709.
58. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
59. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27:1406-12.
60. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-97.
61. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-66.
62. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005;40(suppl 6):S392-400.
63. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients with amphotericin B lipid complex. Clin Infect Dis 2005;40(suppl 6):S401-8.
64. Larkin J, Montero J. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003;20:201-6.
65. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005;41:1217-23.
66. Singh VR, Smith DK, Lawerence J, et al. Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis 1996;23:563-8.
67. Antony S, Dominguez DC, Sotelo E. Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis. J Natl Med Assoc 2003;95:982-5.
68. Stevens DA, Shatsky SA. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin Respir Infect 2001;16:263-9.
69. Chapman SW, Bradsher RW Jr, Campbell GD Jr, Pappas PG, Kauffman CA, for the Infectious Diseases Society of America. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 2000;30:679-83.
70. Chapman SW, Lin AC, Hendricks KA, et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect 1997;12:219-28.
71. Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 1996;22(suppl 2):S102-11.
72. Parker JD, Sarosi GA, Doto IL, Bailey RE, Tosh FE. Treatment of chronic pulmonary histoplasmosis. N Engl J Med 1970;283:225-9.
73. Putnam L, Sutliff W, Larkin J. Histoplasmosis cooperative study: chronic pulmonary histoplasmosis treated with amphotericin B alone and with amphotericin B and triple sulfonamide. Am Rev Respir Dis 1968;97:96-102.
74. Furcolow M. Comparison of treated and untreated severe histoplasmosis. JAMA 1963;183:121-7.
75. Sutliff W, Andrews C, Jones E, Terry R. Histoplasmosis cooperative study: Veterans Administration armed forces cooperative study on histoplasmosis. Am Rev Respir Dis 1964;89:641-50.
76. Baum GL, Larkin JC Jr, Sutliff WD. Follow-up of patients with chronic pulmonary histoplasmosis treated with amphotericin B. Chest 1970;58:562-5.
77. Wheat J, Sarosi G, McKinsey D, et al, for the Infectious Diseases Society of America. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000;30:688-95.
78. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002;137:105-9.
79. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
80. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
81. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases mycoses study group. N Engl J Med 1999;340:764-71.
82. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
83. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-20.
84. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC collaborative study group. Clin Infect Dis 2000;31:1155-63.
85. Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies: a randomized, controlled trial. Eur J Haematol 2004;72:342-7.
86. Tynes BS, Utz JP, Bennett JE, Alling DW. Reducing amphotericin B reactions. A double-blind study. Am Rev Respir Dis 1963;87:264-8.
87. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995;20:755-61.
88. Burks LC, Aisner J, Fortner CL, Wiernik PH. Meperidine for the treatment of shaking chills and fever Arch Intern Med 1980;140:483-4.
89. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322:579-82.
90. Ellis ME, al-Hokail AA, Clink HM, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992;36:172-9.
91. Davies HD, Matlow A, King S, Koren G. Effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992;36:2573-4.
92. Oldfield EC 3rd, Garst PD, Hostettler C, White M, Samuelson D. Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother 1990;34:1402-6.
93. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis 2002;35:891-5.
94. Intermune, Inc. Amphotec (amphotericin B cholesteryl sulfate complex for injection) prescribing information. Brisbane, CA; 2001.
95. Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis 2003;36:1213-20.
96. Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 1998;18:1053-61.
97. Wiwanitkit V. Severe hypertension associated with the use of amphotericin B: an appraisal on the reported cases [letter]. J Hypertens 2006;24:1445.
98. Ferreira E, Perreault MM. Hypertension exacerbated by amphotericin B administration. Ann Pharmacother 1997;31:1407-8.
99. Rowles DM, Fraser SL. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review. Clin Infect Dis 1999;29:1564-5.
100. Sanders SW, Buchi KN, Goddard MS, Lang JK, Tolman KG. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 1991;35:1029-34.
101. Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000;25:879-84.
102. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7.
103. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;111:528-34.
104. Butler WT, Bennett JE, Alling DW, Wertlake PT, Utz JP, Hill GJ 2nd. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964;61:175-87.
105. Bates DW, Su L, Yu DT, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001;60:1452-9.
106. Sabra R, Branch RA. Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimicrob Agents Chemother 1991;35:2509-14.
107. Sawaya BP, Weihprecht H, Campbell WR, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991;87:2097-107.
108. Zager RA, Bredl CR, Schimpf BA. Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int 1992;41:1588-94.
109. Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries [online exclusive article]. Clin Infect Dis 2006;43:e29-38. Available from http://www.journals.uchicago.edu/doi/pdf/10.1086/505969.
110. Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999;43:267-71.
111. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989;87:547-52.
112. Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci 1989;298:299-304.
113. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995;6:154-64.
114. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-94.
115. Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002;186:379-88.
116. Mayer J, Doubek M, Vorlicek J. Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 1999;7:51-5.
117. Girmenia C, Cimino G, Di Cristofano F, Micozzi A, Gentile G, Martino P. Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies. Support Care Cancer 2005;13:987-92.
118. Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002;132:316-20.
119. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003;36:943-51.
120. Lewis RE, Wiederhold NP. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy? Clin Infect Dis 2003;37:871-2.
121. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004;190:1464-71.
122. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006;50:469-73.
123. Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy 2000;20:1335-55.
124. Gurwith M. Clinical efficacy of ampholericin B colloidal dispersion against infections caused by Aspergillus spp. Chemotherapy 1999;45(suppl 1):34-8.
125. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40(suppl 6):S414-21.
126. Miller CB, Waller EK, Klingemann HG, et al. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant 2004;33:543-8.
127. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
128. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
129. Slain D, Miller K, Khakoo R, Fisher M, Wierman T, Jozefczyk K. Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study. Clin Ther 2002;24:1636-42.
130. Hooshmand-Rad R, Reed MD, Chu A, et al. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than- recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections. Clin Ther 2004;26:1652-62.
131. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45:3487-96.
132. Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy 1998;18:874-6.
133. Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother 1985;27:868-71.
134. McChesney JA, Marquardt JF. Hypokalemic paralysis induced by amphotericin B. JAMA 1964;189:1029-31.
135. Marcus N, Garty BZ. Transient hypoparathyroidism due to amphotericin B-induced hypomagnesemia in a patient with β-thalassemia. Ann Pharmacother 2001;35:1042-4.
136. Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am J Med 1984;77:471-4.
137. Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. Nephron 1995;70:235-41.
138. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991;40:302-8.
139. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
140. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-21.
141. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992;117:655-60.
142. Barbaro G, Barbarini G, Calderon W, Grisorio B, Alcini P, Di Lorenzo G. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Candida esophagitis. Gastroenterology 1996;111:1169-77.
143. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997;176:227-32.
144. Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS clinical trials group study 323/mycoses study group study 40. Clin Infect Dis 2005;41:1473-80.
145. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8.
146. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006;34:857-63.
147. Garey KW, Pai MP, Suda KJ, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007;16:919-27.
148. Anaissie EJ, Vadhan-Raj S. Is it time to redefine the management of febrile neutropenia in cancer patients? Am J Med 1995;98:221-3.
149. de Pauw BE, Raemaekers JM, Donnelly JP, Kullberg BJ, Meis JF. An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol 1995;70:83-7.
150. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
151. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
152. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Prevention and treatment of cancer related infections. VI.2007. Available from http://www.nccn.org/professionals/physician_gls/PDF/ fever.pdf. Accessed May 15, 2007.
153. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410.
154. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999;27:1066-72.
155. Garbino J. Fluconazole prophylaxis for critically ill patients at high risk for Candida infection. Clin Infect Dis 2005;41:1690-1.
156. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-8.
157. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005;33:1928-35; quiz 1936.
158. Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004;23:739-44.
159. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994;170:644-52.
160. Karchmer AW, Samore MH, Hadley S, Collins LA, Jenkins RL, Lewis WD. Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc 1994;106:38-47; discussion 47-8.
161. Dromer F, Mathoulin S, Dupont B, Brugiere O, Letenneur L. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French cryptococcosis study group. Clin Infect Dis 1996;22(suppl 2):S154-60.
162. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID mycoses study group and the AIDS clinical trials group. N Engl J Med 1992;326:83-9.
163. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California collaborative treatment group. N Engl J Med 1991;324:580-4.
164. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003;36:1329-31.
165. U.S. National Institutes of Health. Amphotericin alone or in combination with fluconazole for AIDS-associated meningitis. ClinicalTrials.gov. Available from http://clinicaltrials.gov/ct2/show/NCT00145249?term= fluconazole+cryptococcal+meningitis&rank=1. Accessed March 2, 2008.
166. Phillips P, De Beule K, Frechette G, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998;26:1368-73.
167. Janssen Pharmaceutical Products LP. Sporanox (itraconazole) oral solution prescribing information. Titusville, NJ; 2004.
168. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000;30:749-56.
169. Mondal RK, Singhi SC, Chakrabarti A, et al. Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr Crit Care Med 2004;5:561-5.
170. Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group
171. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS [online exclusive article]. Clin Infect Dis 2001;33:e83-90. Available from http://www.journals.uchicago.edu/doi/pdf/10.1086/323020.
172. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID mycoses study group. Am J Med 1992;93:489-97.
173. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent lever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412-22.
174. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
175. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33.
176. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-13.
177. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003;21:4615-26.
178. Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 2004;4:636-43.
179. Pfizer Inc. Vfend (voriconazole) prescribing information. New York, NY; 2006.
180. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54.
181. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41:575-7.
182. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42.
183. Denning DW, Ribaud P Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
184. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451-6.
185. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
186. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002;34:467-76.
187. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-20.
188. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66.
189. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:1179-86.
190. Skiest D, Vasquez J, Graybill J, Walsh TJ. Open label trial of posaconazole for azole-refractory oropharyngeal and esophageal candidiasis in HIV/AIDS patients. Final analysis [abstract]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2004:abstract M-1027.
191. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47.
192. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
193. Schering-Plough. Noxafil (posaconazole) oral suspension, new drug application #022033. Available from http://www.fda.gov/cder/foi/nda/2006/ 022003s000_Noxafil_ClinPharmR.pdf. Accessed October 5, 2007.
194. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005;40:1684-8.
195. Raad H, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403.
196. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases [online exclusive article]. Clin Infect Dis 2006;42:e61-5. Available from http://www.journals.uchicago.edu/doi/pdf/10.1086/500212.
197. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33.
198. Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005;40:1770-6.
199. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12.
200. Pham CP de Feiter PW, van der Kuy PH, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother 2006;40:1456-61.
201. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole [letter]. Ann Intern Med 1999;131:797.
202. Gearhart MO. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994;28:1177-81.
203. Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64:1091-124.
204. Slain D, Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann Pharmacother 2001;35:720-9.
205. Anonymous. Itraconazole: FDA safety alert, cardiovascular and hepatic events. Clin Alert 2001;39:3.
206. Janssen Pharmaceutical Products, LP. Sporanox (itraconazole) oral suspension prescribing information. Titusville, NJ; 2004.
207. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766-7.
208. Ortho Biotech, Inc. Sporanox (itraconazole) injection prescribing information. Raritan, NJ; 2003.
209. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46:235-43.
210. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-34.
211. Kurtz MB, Rex JH. Glucan synthase inhibitors as antifungal agents. Adv Protein Chem 2001;56:423-75.
212. Merck & Co., Inc. Cancidas (caspofungin acetate) for injection prescribing information. West Point, PA;2005.
213. Astellas Pharma, Inc. Mycamine (micafungin sodium) for injection. Tokyo, Japan; January 2008.
214. Pfizer Inc. Eraxis (anidulafungin IV) prescribing information. New York, NY; 2006.
215. Douglas CM, D'lppolito JA, Shei GJ, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997;41:2471-9.
216. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002;49:889-91.
217. Douglas CM, Foor F, Marrinan JA, et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc Natl Acad Sci U S A 1994;91:12907-11.
218. Popolo L, Gualtieri T, Ragni E. The yeast cell-wall salvage pathway. Med Mycol 2001;39(suppl 1):111-21.
219. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35.
220. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002;46:451-7.
221. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294-9.
222. Veroux M, Macarone M, Fiamingo P, et al. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. Transplant Proc 2006;38:1037-9.
223. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
224. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004;48:3407-11.
225. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802.
226. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842-9.
227. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005;21:899-907.
228. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-61.
229. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27.
230. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93.
231. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16.
232. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004;36:372-9.
233. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337-49.
234. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39:770-5.
235. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48:2021-4.
236. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82.
237. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4:25-30.
238. Kartsonis NA, Nielsen J, Douglas CM. Caspofungin: the first in a new class of antifungal agents. Drug Resist Update 2003;6:197-218.
239. Cleary JD, Schwartz M, Rogers PD, de Mestral J, Chapman SW. Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy 2003;23:966-73.
240. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004;6:110-16.
241. Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006;38:47-51.
242. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006;42:1404-13.
243. Herbrecht R, Fohrer C, Nivoix Y. Mycograb for the treatment of invasive candidiasis [letter]. Clin Infect Dis 2006;43:1083; author reply 1083-4.
244. Hodgetts S, Nooney L, Awad S, Matthews R. Mycograb in combination with caspofungin in murine models of candidiasis [abstract]. In: Program and abstracts of the 46th interscience conference on antimicrobial agents and chemotherapy, Washington, DC: American Society for Microbiology, 2006: abstract M-1751.
245. Brummer E, Morrison CJ, Stevens DA. Recombinant and natural γ-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immunol 1985;49:724-30.
246. Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA. In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991;163:849-52.
247. Brummer E, Stevens DA. Candidacidal mechanisms of peritoneal macrophages activated with lymphokines or γ-interferon. J Med Microbiol 1989;28:173-81.
248. Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferon-γ in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994;170:1331-4.
249. Kelleher P, Goodsall A, Mulgirigama A, et al. Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 2006;27:1307-10.
250. Mamishi S, Zomorodian K, Saadat F, Gerami-Shoar M, Tarazooie B, Siadati SA. A case of invasive aspergillosis in CGD patient successfully treated with amphotericin B and INF-γ [letter]. Ann Clin Microbiol Antimicrob 2005;4:4.
251. Najvar L, Bocanegra R, Olivo M, Molina D. Once is enough: single dose aminocandin (AC) therapy of candidemia [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract F-496.
252. Brzankalski G, Bocanegra R, Najvar L, Olivo M. Efficacy of aminocandin (AC) in treatment of Candida glabrata (CG) in mice [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract F-1624.
253. Warn PA, Sharp A, Morrissey G, Denning DW. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. J Antimicrob Chemother 2005;56:590-3.
254. Warn P, Sharp A, Denning D. Dose response curves and dose fractionation studies with aminocandin in a murine model of disseminated aspergillosis [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract F-495.
255. Yan JH, Marino MR, Smith RA, Kanamaluru V, O'Mara EM, Grasela DM. The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J Clin Pharmacol 2006;46:193-200.
256. Gonzalez GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005;43:281-4.
257. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia- Effron G, Monzon A, Rodriguez-Tudela JL. In vitro activity of ravuconazole against 923 clinical isolates of non-dermatophyte filamentous fungi. Antimicrob Agents Chemother 2005;49:5136-8.
258. Gupta AK, Leonardi C, Stoltz RR, Pierce PF, Conetta B. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005;19:437-43.
259. Viljoen J, Mitha I, Heep M, Ghannoum M. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs. fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract LB2-32.
260. Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50:286-93.
261. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006;57:135-8.
262. Warn PA, Denning D, Heep M, Isham N. In vitro activity of a new triazole bal4815 against Candida isolates with decreased fluconazole susceptibility [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract M-1620.
263. Dorsthorst D, Verweij P, Meis J, Mouton J. Pharmacodynamics of BAL4815: a new azole antifungal in a mouse model of systemic infection [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract A-1874.
264. Ghannoum M, Isham N. Antifungal activity of BAL4815, a novel azole against dermatophytes and emerging non-dermatophyte fungi Zygomycetes [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract M-1623.
265. Warn P, Sharp A, Denning D. In vitro activity of BAL4815 against Zygomycetes [abstract]. In: Proceedings of the 16th congress of the International Society for Human and Animal Mycology, Paris, France, 2006: abstract P-0158.
266. Mittendorf J, Kunisch F, Matzke M, Militzer HC, Schmidt A, Schonfeld W. Novel antifungal β-amino acids: synthesis and activity against Candida albicans. Bioorg Med Chem Lett 2003;13:433-6.
267. Petraitiene R, Petraitis V, Kelaher AM, et al. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2005;49:2084-92.
268. Brockmeyer N, Rhunke M, Oreskovic K, Peterson J. A phase II study of icofungipen (PLD-118) in the treatment of oropharyngeal candidiasis (OPC) in HIV-positive patients [abstract]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2004: abstract M-1036.